BGM Group Ltd. (BGM) Stock

About BGM Group Ltd.

Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Qilian Shan Licorice Extract, serving as a raw material for pharmaceutical firms to produce conventional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient utilized by medical preparers for crafting compound licorice oral solutions. BGM also provides Qilian Shan oxytetracycline tablets, formulated to prevent and treat a range of ailments in poultry (chickens, turkeys), livestock (cattle, swine), and humans, in addition to Qilian Shan oxytetracycline APIs for use by pharmaceutical manufacturers. Beyond APIs, the company produces TCM derivatives such as Ahan antibacterial paste, which is designed for managing stubborn chronic skin conditions. Its diverse offerings also encompass heparin products, including heparin sodium preparations essential for pharmaceutical companies developing treatments for cardiovascular and cerebrovascular diseases, as well as hemodialysis applications. Furthermore, BGM supplies natural food products like Zhu Xiaochang sausage casings for culinary use. In the agricultural sector, it offers Xiongguan organic fertilizers, which enhance crop yields, improve soil chemical characteristics, and alleviate compaction, alongside Xiongguan organic-inorganic compound fertilizers engineered to promote superior plant development. Established in 2019, the company operated as Qilian International Holding Group Limited until adopting its current name, BGM Group Ltd, in October 2024.

BGM Group Ltd. is led by CEO Chen Xin, employs 298 people, headquartered in CN, publicly traded since 2003.

BGM Group Ltd. (BGM) stock trades at $7.85 with a market capitalization of $99.60M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.62, reflecting a net loss over the last twelve months, price-to-book of 0.12, price-to-sales of 2.08. Over the past 52 weeks the stock has ranged between $6.45 and $302.40, and currently trades 97.4% below its 52-week high.

On profitability, BGM Group Ltd. generates a return on equity (ROE) of -5.37% (negative, reflecting a net loss), return on capital employed of -2.81%, an operating margin of -23.42%, a net profit margin of -44.22%.

Official website: www.bgmgroupltd.com

BGM Group Ltd. by the numbers, 2017–2025

Between 2017 and 2025 BGM Group Ltd. reported revenue of $23.0M rising to $38.0M, a change of +65.2% across 9 years. Compounded, revenue has grown -5.3% a year over five years, -16.4% over three, 52.0% over the last twelve months. Net profit fell to $-20.0M.

Operating margin went from 5.0% in 2017 to -33.2% in 2025, a fall of 38.2 percentage points. The most recent net margin is -44.22%. On a trailing twelve-month basis to Mar '26, revenue is $75.0M and net profit $-22.0M.

Borrowings fell from $7.0M to $2.0M, cash on hand is $12.0M, cash from operations was $-2.0M in the latest year, positive in 5 of the last 9.

Return on equity has averaged -3.7% over five years, and was -5.1% in the most recent year.

The share price itself has compounded at -56.4% a year over five years, -55.9% over three, -97.3% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

BGM Group Ltd. (BGM) — frequently asked questions